FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS

Their core work

The Gianni Benzi Foundation is an Italian non-profit research foundation focused on improving drug development and clinical research for underserved patient populations — particularly children and rare disease patients. They work at the intersection of regulatory science, clinical trials methodology, and translational research, helping bridge the gap between laboratory discoveries and approved medicines. Their specific contributions include building paediatric research infrastructure, advancing sickle cell disease research in Africa, and supporting European-wide coordination of rare disease data and clinical studies.

What they specialise in

How they've shifted over time

Their early H2020 work (2018) centred squarely on paediatric translational research — building infrastructure for children's drug development and running large-scale clinical trial networks across Europe. From 2019 onward, the focus broadened into rare diseases more generally and shifted toward global health, with the ARISE project bringing sickle cell disease research capacity-building to Africa. This later phase also shows a growing emphasis on data sharing, FAIR principles, patient empowerment, and training — suggesting a move from pure clinical research toward research ecosystem development.

Moving from European paediatric clinical infrastructure toward globally-oriented rare disease research with strong emphasis on open data, training, and capacity-building in low-resource settings.

How they like to work

The Foundation operates primarily as a specialist partner within very large consortia — c4c and EJP RD are major European programmes with dozens of partners each, which accounts for their 221 unique partners across 45 countries. They have also demonstrated coordination capability, leading the ARISE project as coordinator, which shows they can manage international research programmes when the topic aligns with their core mission. Their participation as a third party in ID-EPTRI suggests they also offer niche expertise to infrastructure-building efforts without needing a full consortium role.

Despite only 4 projects, they have an exceptionally wide network of 221 partners across 45 countries, driven by participation in two flagship European programmes (c4c and EJP RD). Their reach extends well beyond Europe into Africa through the ARISE project, giving them unusual global connectivity for a small Italian foundation.

What sets them apart

What sets the Gianni Benzi Foundation apart is the rare combination of deep regulatory and clinical trials expertise applied specifically to populations that pharmaceutical companies often neglect: children, neonates, and rare disease patients. As a non-profit foundation rather than a university or hospital, they occupy a neutral convening position — able to bridge academic research, regulatory science, and patient advocacy without commercial bias. Their ARISE coordination also demonstrates a commitment to extending European research standards to African contexts, a profile few organisations of their size can claim.

Highlights from their portfolio

• c4c
  Their largest project by far (EUR 2.8M funding), c4c is a flagship European network for paediatric clinical trials — placing the Foundation at the heart of children's medicine research infrastructure.
• ARISE
  Their only coordinator role — an Africa-focused sickle cell disease project that demonstrates both leadership capability and an unusual global health dimension for a small Italian foundation.
• EJP RD
  Participation in the European Joint Programme on Rare Diseases connects them to the continent's primary rare disease research coordination mechanism, with emphasis on FAIR data and patient empowerment.